PHYOX3: Nedosiran Long-Term Safety and Efficacy in Patients With Primary Hyperoxaluria Type 1
Nedosiran was well-tolerated, reduced average Uox levels, reduced kidney stone occurrence, and maintained stable renal function for over 3 years.
Authors
- Gema Ariceta (ORCID: https://orcid.org/0000-0003-1763-1098)
- Jaap W. Groothoff (ORCID: https://orcid.org/0000-0002-8467-3506)
- Graham Lipkin
- Gesa Schalk
- John Charles Lieske (ORCID: https://orcid.org/0000-0002-0202-5944)
- Anne‐Laure Sellier‐Leclerc (ORCID: https://orcid.org/0000-0001-9902-0850)
- Verity Rawson
- Bernd Höppe (ORCID: https://orcid.org/0000-0002-8120-3306)
- Sara Estupiñan Torres
- Jing Zhou (ORCID: https://orcid.org/0000-0003-2177-4569)
- Shabbir H. Moochhala (ORCID: https://orcid.org/0000-0002-8941-6883)
Institutions
- Hebron University (PS)
- Universitat Autònoma de Barcelona (ES)
- University Hospitals Birmingham NHS Foundation Trust (GB)
- Mayo Clinic (US)
- Hospital Universitario de Canarias (ES)
- The Royal Free Hospital (GB)
- Emma Kinderziekenhuis (NL)
- Hospices Civils de Lyon (FR)
- Novo Nordisk (United States) (US)
- Bonnier Technology Group (Germany) (DE)
- Amsterdam University Medical Centers (NL)
- University College London (GB)
- University of Amsterdam (NL)
Publication Details
- Journal
- Kidney International Reports
- Published
- 2025-03-26
- DOI
- https://doi.org/10.1016/j.ekir.2025.03.031
- Citations
- 6
- Primary Topic
- Neonatal Health and Biochemistry
- Type
- article
- Field-Weighted Citation Impact
- 20.96
Funders
- Novo Nordisk